Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25749124 | 0.81 | L3MBTL1 (0.42) | L3MBTL1GABRA1NUDT1TNKS | |
| SCHEMBL24198026 | 0.81 | L3MBTL1 (0.46) | L3MBTL1NUDT1TNKS | |
| SCHEMBL24857557 | 0.79 | L3MBTL1 (0.41) | L3MBTL1NUDT1TNKS | |
| SCHEMBL16705075 | 0.77 | L3MBTL1 (0.62) | L3MBTL1HTR3ANUDT1TNKS | |
| SCHEMBL22490650 | 0.76 | L3MBTL1 (0.43) | L3MBTL1HTR3ANUDT1TNKSAURKA | |
| SCHEMBL14006669 | 0.74 | NUDT1 (0.47) | L3MBTL1HTR3ANUDT1AURKA | |
| SCHEMBL6370588 | 0.74 | L3MBTL1 (0.42) | L3MBTL1HTR3ANUDT1TNKSAURKA | |
| SCHEMBL25974824 | 0.73 | L3MBTL1 (0.41) | L3MBTL1HTR3ANUDT1TNKSAURKA | |
| SCHEMBL1983144 | 0.73 | L3MBTL1 (0.49) | L3MBTL1HTR3ANUDT1TNKSAURKA | |
| SCHEMBL20125020 | 0.72 | L3MBTL1 (0.41) | L3MBTL1NUDT1TNKSKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | L3MBTL1 3524/4885GABRA1 1181/4885GABRB1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.